Literature DB >> 9009155

Breast-cancer mortality in a non-randomized trial on mammographic screening in women over age 65.

J A Van Dijck1, A L Verbeek, L V Beex, J H Hendriks, R Holland, M Mravunac, H Straatman, J M Werre.   

Abstract

Recent case-referent studies in the Nijmegen breast-screening programme have shown a reduction in breast-cancer mortality of approximately 50% due to screening of women aged 65 years and older. In this type of study, however, the results may be biased because of self-selection. The purpose of our present study was to compare the breast-cancer mortality rate in a population invited for screening with that of a reference population from an area without a screening programme. In 1977-1978, 6773 women aged 68-83 years were enrolled in the mammographic screening programme in Nijmegen, The Netherlands. The women were followed up until 31 December, 1990. The reference population consisted of women from the same birth cohort from Arnhem, a neighbouring city without mass screening, for whom the entry date was 1 January, 1978. The ratios of the Nijmegen and Arnhem breast-cancer mortality rates with 95% confidence intervals (CI) were calculated. In the study period, 173 patients were diagnosed with primary breast cancer in Nijmegen vs. 183 in Arnhem; 40 Nijmegen patients had died of breast cancer vs. 51 Arnhem patients. The cumulative mortality-rate ratio was 0.80 (95% CI = 0.53-1.22). In the periods 1978-1981, 1982-1985 and 1986-1990, the mortality rate ratios were 1.44 (95% CI = 0.67-3.10), 081 (95% CI = 0.37-1.79) and 0.53 (95% CI = 0.27-1.04), respectively. After adjustment for the difference in incidence rate that existed between the Nijmegen and Arnhem populations, mammographic screening of women older than 65 can be expected to yield a 40% reduction in breast-cancer mortality after 10 years.

Entities:  

Mesh:

Year:  1997        PMID: 9009155     DOI: 10.1002/(sici)1097-0215(19970117)70:2<164::aid-ijc5>3.0.co;2-v

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  Mammographic screening in older women. Is it worthwhile?

Authors:  J A van Dijck; M J Broeders; A L Verbeek
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

2.  Mammography interval and breast cancer mortality in women over the age of 75.

Authors:  Michael S Simon; Sylvia Wassertheil-Smoller; Cynthia A Thomson; Roberta M Ray; F Allan Hubbell; Lawrence Lessin; Dorothy S Lane; Lew H Kuller
Journal:  Breast Cancer Res Treat       Date:  2014-09-25       Impact factor: 4.872

Review 3.  Breast Cancer Screening in Older Women: The Importance of Shared Decision Making.

Authors:  Sarina Schrager; Viktoriya Ovsepyan; Elizabeth Burnside
Journal:  J Am Board Fam Med       Date:  2020 May-Jun       Impact factor: 2.657

4.  Screen-detected breast cancers have a lower mitotic activity index.

Authors:  R P Groenendijk; P Bult; L Tewarie; P G Peer; R F van der Sluis; T J Ruers; T Wobbes
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

5.  Mammography service screening and breast cancer mortality in New Zealand: a National Cohort Study 1999-2011.

Authors:  Stephen Morrell; Richard Taylor; David Roder; Bridget Robson; Marli Gregory; Kirsty Craig
Journal:  Br J Cancer       Date:  2017-02-09       Impact factor: 7.640

Review 6.  Worldwide Review and Meta-Analysis of Cohort Studies Measuring the Effect of Mammography Screening Programmes on Incidence-Based Breast Cancer Mortality.

Authors:  Amanda Dibden; Judith Offman; Stephen W Duffy; Rhian Gabe
Journal:  Cancers (Basel)       Date:  2020-04-15       Impact factor: 6.639

7.  Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines.

Authors:  L Wyld; D K Garg; I D Kumar; H Brown; M W R Reed
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

8.  Screening mammography & breast cancer mortality: meta-analysis of quasi-experimental studies.

Authors:  Veronica L Irvin; Robert M Kaplan
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.